At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research

Over 30 presentations at ASCO and EHA leverage clonoSEQ MRD testing to assess novel therapies and support MRD-guided patient care across blood cancers

Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.